Immunological Efficacy of a Prime-boost Strategy Combining a 7-valent Pneumococcal Conjugate Vaccine (PCV) Followed by a 23-valent Pneumococcal Polysaccharide Vaccine (PPV) Versus PPV Alone in HIV-infected Adults. ANRS 114 PNEUMOVAC.
Immunological Efficacy of a Prime-boost Strategy Combining a 7-valent Pneumococcal Conjugate Vaccine (PCV) Followed by a 23-valent Pneumococcal Polysaccharide Vaccine (PPV) Versus PPV Alone in HIV-infected Adults. ANRS 114 PNEUMOVAC.
Streptococcus pneumoniae is the major cause of bacterial infection in HIV-infected patients. The current pneumococcal vaccine is poorly efficacious in patients with a CD4 cell count lower than 500/mm3. This study will test the efficacy and safety of a new pneumococcal vaccine strategy in patients with a CD4 cell count between 200 and 500/mm3.
Streptococcus pneumoniae (SP) is the major cause of bacterial infection in HIV-infected patients. The 23-valent pneumococcal polysaccharide (PPV) is poorly immunogenic in patients with CD4 below 500 cells/mm3. The purpose of this multicentric national study is to evaluate whether a prime with a 7-valent pneumococcal conjugate vaccine (PCV), able to induce immunological memory, would improve immunogenicity against SP polysaccharides. 212 HIV-1 infected patients, with a CD4 count between 200 and 500/mm3, will be randomly assigned to one of two vaccine groups: PCV at Week 0 followed by PPV at Week 4 or PPV alone at Week 4. Evaluation will be done at week 8. The primary endpoint is the proportion of patients who had antibody responses against 7 pneumococcal polysaccharides at Week 8. Secondary endpoints include the persistence of antibody responses at Weeks 24 and 96, vaccines safety and occurrence of pneumococcal disease over time.
Inclusion Criteria:
Exclusion Criteria: